UNS markets Seacod, considered one of India’s top-selling cod liver oil capsule manufacturers. The corporate is anticipated to be valued at round ₹3,000 crore. Funding financial institution Rothschild has been appointed to advise Kedaara on the sale course of, the individuals cited above mentioned.
Common NutriScience was created in 2021 as a strategic partnership between Kedaara Capital and Common Medicare. The corporate was shaped after buying 16 nutraceutical manufacturers from Sanofi India for ₹587 crore. The portfolio included main manufacturers reminiscent of Seacod, ECod, CoQ, Primosa and Collaflex, together with a big a part of the advertising and distribution workforce related to these merchandise.
The corporate reported income of about ₹230 crore and Ebitda of ₹61 crore in FY25. In line with sources, income is estimated to have grown to ₹350-400 crore in FY26, with Ebitda reaching round ₹100 crore.
Kedaara is looking for a valuation of roughly 30 instances the newest Ebitda, which a number of potential patrons imagine is steep. “The enterprise is extra realistically valued within the vary of 20-25 instances Ebitda,” mentioned a fund supervisor at a worldwide non-public fairness agency, requesting anonymity.
Kedaara presently holds a 58.8% stake in Common NutriScience, whereas Common Medicare owns 28.1%. Common Medicare founder Vikram Bodhraj Tannan holds a 2.7% stake and Shailesh Ayyangar, former managing director of Sanofi India, owns 1.7%, with the remaining stake held by different traders, in keeping with Tracxn knowledge.
Mail despatched to Kedaara Capital didn’t elicit any responses until the press time.India’s nutraceuticals sector has witnessed rising investor curiosity in recent times. Investments within the section elevated 2.5 instances between 2020 and 2023 in contrast with the 2016-2019 interval, whereas the worldwide market noticed a 1.7-fold improve over the identical timeframe, in keeping with consulting agency Kearney.
The surge has been pushed by rising disposable incomes and rising well being consciousness after the Covid-19 pandemic, which has made day by day dietary supplements more and more widespread in Indian households. Digital marketplaces and direct-to-consumer platforms have additionally accelerated adoption by making nutraceutical merchandise extra accessible, the report added.
Globally, the nutraceuticals market is valued at over $520 billion and is rising at a compound annual charge of 8-9%. Asia-Pacific, the biggest regional market, is increasing at about 8.8% CAGR. In India, the sector is estimated to be price round $8 billion and is projected to develop at about 11% CAGR between 2023 and 2027.
The sector has additionally seen a flurry of mergers, acquisitions and personal fairness exercise as pharmaceutical and FMCG corporations push deeper into preventive healthcare.
